Trevena to Participate in the Upcoming January Conferences

Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) has announced the participation of CEO Carrie Bourdow and CFO Barry Shin in three virtual investor conferences this January. The conferences include the LifeSci Partners Annual Corporate Access Event from January 5-7, where a panel discussion on biopharmaceutical commercial launches will take place on January 5 at 7:30 AM ET. The company will also participate in the H.C. Wainwright BioConnect Virtual Conference from January 10-12 and BIO Partnering at JPM from January 10-13. Trevena focuses on CNS disorders and has one approved product, OLINVYK®.

CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, Chief Financial Officer, will be participating in three January virtual investor and partnering conferences, with additional details below.

Conference Details

LifeSci Partners - 11^th Annual Corporate Access Event & Panel Discussion
      Wednesday, January 5^th - Friday, January 7^th  Registration Link

      Panel Discussion on Biopharmaceutical Commercial Launches
      Wednesday, January 5^th at 7:30am ET
      https://wsw.com/webcast/lifesci3/panel1/2377650

H.C. Wainwright BioConnect Virtual Conference
      Monday, January 10^th - Wednesday, January 12^th  Registration Link

BIO Partnering at JPM
      Monday, January 10^th - Thursday, January 13^th  Registration Link

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.  

For more information, please visit www.Trevena.com 

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576

PR & Media Contact:

Sasha Bennett
Associate Vice President
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409 

FAQ

What conferences is Trevena participating in January 2022?

Trevena is participating in three virtual conferences: the LifeSci Partners Annual Corporate Access Event from January 5-7, the H.C. Wainwright BioConnect Virtual Conference from January 10-12, and BIO Partnering at JPM from January 10-13.

Who is representing Trevena at the investor conferences in January 2022?

Carrie Bourdow, President & CEO, and Barry Shin, Chief Financial Officer, will represent Trevena at the investor conferences.

What is the date for the panel discussion on biopharmaceutical commercial launches?

The panel discussion on biopharmaceutical commercial launches is scheduled for January 5, 2022, at 7:30 AM ET.

What is Trevena's stock symbol?

Trevena's stock symbol is TRVN.

What is OLINVYK® and its indication?

OLINVYK® (oliceridine) injection is an approved product indicated for the management of acute pain severe enough to require an intravenous opioid analgesic.